Robert W. Baird Issues Positive Forecast for Taysha Gene Therapies (NASDAQ:TSHA) Stock Price

Taysha Gene Therapies (NASDAQ:TSHA) had its target price hoisted by Robert W. Baird from $7.00 to $12.00 in a research report report published on Thursday morning, MarketBeat.com reports. They currently have an outperform rating on the stock.

Other equities research analysts also recently issued research reports about the company. Wells Fargo & Company lifted their target price on Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an “overweight” rating in a report on Wednesday, August 13th. Needham & Company LLC lifted their target price on Taysha Gene Therapies from $8.00 to $10.00 and gave the stock a “buy” rating in a report on Thursday. Chardan Capital boosted their price target on Taysha Gene Therapies from $9.00 to $10.00 and gave the company a “buy” rating in a report on Tuesday, August 12th. Finally, Bank of America assumed coverage on Taysha Gene Therapies in a report on Friday, July 11th. They issued a “buy” rating and a $8.00 price target for the company. Nine analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $9.00.

Taysha Gene Therapies Trading Up 53.5%

Taysha Gene Therapies stock opened at $4.88 on Thursday. The company has a quick ratio of 12.48, a current ratio of 12.48 and a debt-to-equity ratio of 0.17. Taysha Gene Therapies has a 52 week low of $1.05 and a 52 week high of $4.92. The company has a market capitalization of $1.33 billion, a price-to-earnings ratio of -14.35 and a beta of 0.99. The stock has a 50-day moving average price of $2.98 and a 200 day moving average price of $2.45.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Tuesday, August 12th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). Taysha Gene Therapies had a negative return on equity of 78.44% and a negative net margin of 1,144.97%.The firm had revenue of $1.99 million for the quarter, compared to analyst estimates of $1.61 million. Sell-side analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $3.23, for a total value of $646,000.00. Following the completion of the sale, the insider directly owned 1,006,439 shares in the company, valued at $3,250,797.97. The trade was a 16.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.78% of the stock is owned by company insiders.

Institutional Trading of Taysha Gene Therapies

A number of institutional investors and hedge funds have recently made changes to their positions in TSHA. Jefferies Financial Group Inc. increased its position in shares of Taysha Gene Therapies by 4,105.3% in the second quarter. Jefferies Financial Group Inc. now owns 10,313,733 shares of the company’s stock valued at $23,825,000 after buying an additional 10,068,479 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth approximately $11,178,000. MPM Bioimpact LLC purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth approximately $6,823,000. Octagon Capital Advisors LP increased its position in shares of Taysha Gene Therapies by 17.7% during the second quarter. Octagon Capital Advisors LP now owns 12,592,500 shares of the company’s stock worth $29,089,000 after purchasing an additional 1,892,500 shares in the last quarter. Finally, Stempoint Capital LP purchased a new stake in shares of Taysha Gene Therapies during the second quarter worth approximately $2,781,000. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.